Novi steroidni derivati sintetizirani iz 3betha-hidroksiandrosten-17-ona by NEHAD A. ABD EL-LATIF et al.
Natural steroids and their synthetic congeners were extensively studied during the
last decade (1, 2). In a previous work, some new heterocyclic compounds showing anti-
parkinsonian (3), antitumor (4–6), antimicrobial (7–10) and anti-inflammatory (11) activ-
ity were synthesized. We found that certain substituted steroidal derivatives showed
androgenic, anabolic and anti-inflammatory activities (12). Steroidal pyrazolines are an
interesting group of compounds, many of which possess wide spread pharmacological
properties such as analgesic, antipyretic and antiandrogenic activities (13, 14). These de-
rivatives are also well known for their pronounced anti-inflammatory (15) activity and
are used as potent antidiabetic agents (16). In addition, the pharmacological and antitu-
mor activities of many heterocyclic compounds have been reviewed (17–19). Recently,
nitrogenous derivatives exhibited a general ionophoric potency for divalent cations (20)
and are used as novel thiocyanate-selective membrane sensors (21). In view of these re-
ports and in continuation of our previous work in heterocyclic chemistry, we have
herein synthesized some new compounds containing steroidal structure for the evalua-
tion of androgenic-anabolic activity as compared to testosterone as standard drug (Fig.
1).
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roidal derivatives using 3-hydroxyandrosten-17-one
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EXPERIMENTAL
Melting points were determined on an Electrothermal IA 9000 apparatus (Electro-
thermal, UK) and are uncorrected. Elemental analyses for the final compounds were
performed on Elementar, Vario EL (USA) at the Microanalytical Unit, National Research
Centre, Cairo Egypt, and were found within  0.4% of the theoretical values. The IR
spectra (KBr) were recorded on an FT IR-8201 PC Spectrophotometer (Shimadzu, Japan).
The 1H NMR spectra were measured with Jeol 270 MHz (Japan) in DMSO-d6 and the
chemical shifts were recorded in (d, ppm) relative to TMS. Mass spectra were run at 70
eV with a Finnigan SSQ 7000 (thermo-instrument system incorporation, USA) spectro-
meter using EI. The reactions were followed by TLC (silica gel, aluminum sheets 60 F254,
Merck, Germany). Testosterone and dehydroepiandrosterone were purchased from Ald-
rich (Germany).
Physicochemical and spectral data for the synthesized compounds are given in Tab-
les I and II, respectively.
Synthesis of 17-cyano-17-methylamino-androst-5-en-3-ol (1a)
and 17-cyano-17-phenylamino-androst-5-en-3-ol (1b)
To a stirred solution of dehydroepiandrosterone (0.29 g, 1 mmol) in absolute ethanol
(25 mL), the appropriate primary amine, namely, methylamine or aniline (1 mmol) in et-
hanol (5 mL) was added dropwise. Hydrochloric acid (5 mL, 10%) was added to the re-
action mixture; then, potassium cyanide (0.1g, 1 mmol) in water (10 mL) was added
dropwise. The reaction mixture was stirred at room temperature for 96 hours, diluted
with water (100 mL) and neutralized with sodium bicarbonate (10%). The resulting mix-
ture was extracted with chloroform, washed with water, dried over anhydrous sodium
sulphate and evaporated under reduced pressure. The obtained residue was solidified
with diethyl ether, the obtained solid was filtered off, dried and crystallized from the
proper solvent to give the corresponding carbonitriles 1a,b, respectively (Scheme 1).
Synthesis of 17-cyano-17-N-methyl-N-(1,1-diaminoethyl)androst-5-en-3-ol (2a)
and 17-cyano-17-N-phenyl-N-(1,1-diaminoethyl)androst-5-en-3-ol (2b)
A mixture of 1a,b (1 mmol) and dimethylamino-2-chloroethane (0.17 g, 1.2 mmol)
was refluxed for 7 hours in the presence of triethylamine (0.2 mL) as a catalyst in benze-
ne. The reaction mixture was washed with water, 10% sodium bicarbonate, then with
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Fig. 1. Testosterone structural formula.
water and dried over anhydrous sodium sulphate. The benzene part was evaporated
under reduced pressure and the residue obtained was solidified with n-hexane. The ob-
tained solid was filtered off, dried and crystallized from the proper solvent to give the
derivatives 2a,b, respectively (Scheme 1).
Synthesis of 17-cyano-17-N-methyl-N-(piperidin-1-ylmethyl)aminoandrost-5-en-3-ol (3a)
and 17-cyano-17-N-phenyl-N-(piperidin-1-ylmethyl)aminoandrost-5-en-3-ol (3b)
A mixture of carbonitrile derivatives 1a,b (1 mmol) and piperidine (4 mmol) was
refluxed for 2 hours in the presence of powdered paraformaldehyde (12 mg) in 1% hy-
drochloric acid in ethanol (15 mL). The reaction mixture was concentrated under redu-
ced pressure to dryness; the solid formed was collected by filtration, washed with ethanol,
dried and crystallized from the proper solvent to afford the corresponding piperidenyl
derivatives 3a,b, respectively (Scheme 1).
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1a CH3 98 281 +91 White powder (MeOH) C21H32N2O (328.49)
1b C6H5 84 316 +76 Pale yellow powder (AcOEt) C26H34N2O (390.56)
2a CH3 81 217 +79 White powder (AcOMe) C25H41N3O (399.62)
2b C6H5 76 271 +94 White powder (MeOH) C30H43N3O (461.69)
3a CH3 68 235 +88 White powder (EtOH) C27H43N3O (425.65)
3b C6H5 77 286 +96 White powder (EtOH) C32H45N3O (487.72)
4a CH3 64 196 +66 White powder (AcOH) C25H36N2O3 (412.57)
4b C6H5 72 216 +86 White powder (AcOH) C30H38N2O3 (474.64)
5a CH3 65 288 +69 White powder (MeOH) C25H30F6N2O3 (520.51)
5b C6H5 68 249 +79 Pale yellow powder (MeOH) C30H32F6N2O3 (582.58)
6a CH3 55 211 +92 White (MeOH) C21H38N2O (334.54)
6b C6H5 65 218 +76 White powder (AcOEt) C26H40N2O (396.61)
7a CH3 67 199 +96 White (AcOMe) C21H36N2O (332.52)
7b C6H5 72 148 +79 White powder (MeOH) C26H38N2O (394.60)
8a CH3 55 188 +89 White powder (EtOH) C21H34N2O2 (346.51)
8b C6H5 49 198 +77 Orange powder (EtOH) C26H36N2O2 (408.58)
9a CH3 60 252 +95 White powder (AcOH) C21H33NO3 (347.49)
9b C6H5 62 249 +75 White powder (AcOH) C26H35NO3 (409.56)
10a CH3 69 207 +93 White powder (MeOH) C21H31NO3 (345.48)
10b C6H5 78 187 +76 White powder (MeOH) C26H33NO3 (407.55)
11a CH3 80 178 +88 Pale yellow powder (AcOH) C23H37N3O (371.56)
11b C6H5 76 213 +79 White powder (MeOH) C28H39N3O (433.63)
a Confirmed by elemental analysis showing values within  0.4% of the theoretical values unless otherwise
stated.
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0.76 (s, 3H, CH3, C-19), 0.88 (s, 3H, CH3, C-18), 0.96–1.04
(m, 1H, CH), 1.15–1.25 (m, 4H, 2CH2), 1.42–1.56 (m, 6H,
3CH2), 1.60–1.80 (m, 4H, 2CH2), 1.94–1.98 (m, 1H, CH),
2.38 (s, 3H, N-CH3), 2.42–2.48 (m, 2H, CH2), 2.56–2.59 (m,
1H, CH), 3.55–3.60 (m, 1H, 3-CH), 3.92 (s, 1H, NH, ex-
changeable with D2O), 5.58–5.64 (m, 1H, CH, C-6), 10.00









0.78 (s, 3H, CH3, C-19), 0.87 (s, 3H, CH3, C-18), 0.95–1.05
(m, 1H, CH), 1.10–1.24 (m, 4H, 2CH2), 1.43–1.55 (m, 6H,
3CH2), 1.62–1.79 (m, 4H, 2CH2), 1.97–2.04 (m, 1H, CH),
2.44–2.50 (m, 2H, CH2), 2.58–2.62 (m, 1H, CH), 3.56–3.64
(m, 1H, 3-CH), 4.05 (s, 1H, NH, exchangeable with
D2O), 5.55–5.65 (m, 1H, CH, C-6), 7.23–7.50 (m, 5H,








0.78 (s, 3H, CH3, C-19), 0.94 (s, 3H, CH3, C-18), 0.96–1.00
(m, 1H, CH), 1.10–1.23 (m, 4H, 2CH2), 1.38–1.55 (m, 6H,
3CH2), 1.62–1.79 (m, 4H, 2CH2), 1.82–1.85 (m, 4H, 2 CH2),
1.97–2.00 (m, 1H, CH), 2.32, 2.36, 2.39 (3s, 9H, 3 
N-CH3), 2.44–2.48 (m, 2H, CH2), 2.55–2.60 (m, 1H, CH),
3.54–3.61 (m, 1H, 3-CH), 5.60-5.65 (m, 1H, CH, C-6), 9.98








0.74 (s, 3H, CH3, C-19), 0.89 (s, 3H, CH3, C-18), 0.98–1.05
(m, 1H, CH), 1.16–1.25 (m, 4H, 2CH2), 1.41–1.57 (m, 6H,
3CH2), 1.64–1.80 (m, 4H, 2CH2), 1.85–1.88 (m, 4H, 2 CH2),
1.96–2.05 (m, 1H, CH), 2.34, 2.36 (2s, 6H, 2  N-CH3),
2.45–2.50 (m, 2H, CH2), 2.56–2.60 (m, 1H, CH), 3.57–3.64
(m, 1H, 3-CH), 5.58–5.66 (m, 1H, CH, C-6), 7.18–7.46 (m,








0.75 (s, 3H, CH3, C-19), 0.91 (s, 3H, CH3, C-18), 0.96–1.00
(m, 1H, CH), 1.10–1.23 (m, 4H, 2CH2), 1.38–1.55 (m, 6H,
3CH2), 1.58–1.62 (m, 6H, 3CH2), 1.65–1.79 (m, 4H, 2CH2),
1.97–2.00 (m, 1H, CH), 2.20–2.26 (m, 4H, 2CH2), 2.36 (s,
3H, N-CH3), 2.44–2.48 (m, 2H, CH2), 2.55–2.60 (m, 1H,
CH), 3.42 (s, 2H, N-CH2-N), 3.54–3.61 (m, 1H, 3-CH),









0.79 (s, 3H, CH3, C-19), 0.95 (s, 3H, CH3, C-18), 0.98–1.02
(m, 1H, CH), 1.10–1.23 (m, 4H, 2CH2), 1.38–1.55 (m, 6H,
3CH2), 1.56–1.60 (m, 6H, 3CH2), 1.66–1.79 (m, 4H, 2CH2),
1.95–2.05 (m, 1H, CH), 2.24–2.28 (m, 4H, 2CH2), 2.42–2.46
(m, 2H, CH2), 2.53–2.62 (m, 1H, CH), 3.40 (s, 2H,
N-CH2-N), 3.52–3.64 (m, 1H, 3-CH), 5.56–5.61 (m, 1H,
CH, C-6), 7.18–7.46 (m, 5H, Ar-H), 10.02 (s, 1H, OH, ex-
changeable with D2O)
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0.77 (s, 3H, CH3, C-19), 0.92 (s, 3H, CH3, C-18), 1.00–1.05
(m, 1H, CH), 1.18–1.26 (m, 4H, 2CH2), 1.40–1.55 (m, 6H,
3CH2), 1.63–1.78 (m, 4H, 2CH2), 1.95–2.00 (m, 1H, CH),
2.23 (s, 3H, CO-CH3), 2.34 (s, 3H, N-CH3), 2.40–2.50 (m,
2H, CH2), 3.65 (s, 3H, COO-CH3), 2.56–2.62 (m, 1H, CH),









0.79 (s, 3H, CH3, C-19), 0.90 (s, 3H, CH3, C-18), 0.99–1.04
(m, 1H, CH), 1.16–1.24 (m, 4H, 2CH2), 1.43–1.53 (m, 6H,
3CH2), 1.62–1.80 (m, 4H, 2CH2), 1.98–2.04 (m, 1H, CH),
2.25 (s, 3H, CO-CH3), 2.41–2.53 (m, 2H, CH2), 3.66 (s, 3H,
COO-CH3), 2.58–2.62 (m, 1H, CH), 3.52–3.56 (m, 1H,











0.79 (s, 3H, CH3, C-19), 0.98 (s, 3H, CH3, C-18), 1.05–1.10
(m, 1H, CH), 1.20–1.27 (m, 4H, 2CH2), 1.45–1.54 (m, 6H,
3CH2), 1.65–1.82 (m, 4H, 2CH2), 1.96–2.05 (m, 1H, CH),
2.35 (s, 3H, N-CH3), 2.44–2.48 (m, 2H, CH2), 2.53–2.61 (m,











0.79 (s, 3H, CH3, C-19), 0.92 (s, 3H, CH3, C-18), 0.98–1.06
(m, 1H, CH), 1.14–1.25 (m, 4H, 2CH2), 1.45–1.56 (m, 6H,
3CH2), 1.60–1.81 (m, 4H, 2CH2), 1.96–2.00 (m, 1H, CH),
2.43–2.52 (m, 2H, CH2), 2.59–2.64 (m, 1H, CH), 3.54–3.58










0.81 (s, 3H, CH3, C-19), 0.96 (s, 3H, CH3, C-18), 0.99–1.08
(m, 1H, CH), 1.22–1.26 (m, 4H, 2CH2), 1.41–1.55 (m, 6H,
3CH2), 1.62–1.79 (m, 4H, 2CH2), 1.98–2.02 (m, 1H, CH),
2.36 (s, 3H, N-CH3), 2.40–2.45 (m, 2H, CH2), 2.52–2.57 (m,
1H, CH), 3.39 (s, 2H, CH2-N), 3.50–3.61 (m, 1H, 3-CH),
3.75 (s, 2H, NH2, exchangeable with D2O), 3.98 (s, 1H,
NH, exchangeable with D2O), 5.58–5.62 (m, 1H, CH, C-6),









0.79 (s, 3H, CH3, C-19), 0.94 (s, 3H, CH3, C-18), 0.98–1.05
(m, 1H, CH), 1.24–1.28 (m, 4H, 2CH2), 1.42–1.58 (m, 6H,
3CH2), 1.64–1.83 (m, 4H, 2CH2), 1.96–2.04 (m, 1H, CH),
2.41–2.47 (m, 2H, CH2), 2.54–2.59 (m, 1H, CH), 3.38 (s,
2H, CH2-N), 3.53–3.64 (m, 1H, 3-CH), 3.76 (s, 2H, NH2,
exchangeable with D2O), 3.99 (s, 1H, NH, exchangeable
with D2O), 5.56–5.63 (m, 1H, CH, C-6), 7.21–7.36 (m, 5H,









0.80 (s, 3H, CH3, C-19), 0.92 (s, 3H, CH3, C-18), 0.99–1.02
(m, 1H, CH), 1.16–1.27 (m, 4H, 2CH2), 1.39–1.57 (m, 6H,
3CH2), 1.63–1.81 (m, 6H, 3CH2), 1.97–2.05 (m, 1H, CH),
2.34 (s, 3H, N-CH3), 2.44–2.48 (m, 2H, CH2), 2.56–2.65 (m,
1H, CH), 3.00–3.10 (m, 1H, 5-CH), 3.37 (s, 2H, CH2-N),
3.53–3.60 (m, 1H, 3-CH), 3.80 (s, 2H, NH2, exchangeable
with D2O), 4.02 (s, 1H, NH, exchangeable with D2O), 9.98
(s, 1H, OH, exchangeable with D2O)
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0.79 (s, 3H, CH3, C-19), 0.88 (s, 3H, CH3, C-18), 0.97–1.00
(m, 1H, CH), 1.15–1.25 (m, 4H, 2CH2), 1.42–1.56 (m, 6H,
3CH2), 1.61–1.80 (m, 6H, 3CH2), 1.99–2.06 (m, 1H, CH),
2.43–2.49 (m, 2H, CH2), 2.57–2.64 (m, 1H, CH), 3.05–3.15
(m, 1H, 5-CH), 3.35 (s, 2H, CH2-N), 3.54–3.62 (m, 1H,
3-CH), 3.78 (s, 2H, NH2, exchangeable with D2O), 4.00
(s, 1H, NH, exchangeable with D2O), 7.22–7.35 (m, 5H,











0.79 (s, 3H, CH3, C-19), 0.94 (s, 3H, CH3, C-18), 0.95–1.05
(m, 1H, CH), 1.16–1.25 (m, 4H, 2CH2), 1.44–1.54 (m, 6H,
3CH2), 1.61–1.82 (m, 4H, 2CH2), 1.96–2.05 (m, 1H, CH),
2.33 (s, 3H, N-CH3), 2.42–2.49 (m, 2H, CH2), 2.57–2.64 (m,
1H, CH), 3.52–3.63 (m, 1H, 3-CH), 3.74 (s, 2H, NH2, ex-
changeable with D2O), 3.98 (s, 1H, NH, exchangeable wi-












0.81 (s, 3H, CH3, C-19), 0.93 (s, 3H, CH3, C-18), 0.99–1.05
(m, 1H, CH), 1.15–1.24 (m, 4H, 2CH2), 1.43–1.57 (m, 6H,
3CH2), 1.65–1.80 (m, 4H, 2CH2), 1.98–2.02 (m, 1H, CH),
2.40–2.48 (m, 2H, CH2), 2.54–2.61 (m, 1H, CH), 3.50–3.64
(m, 1H, 3-CH), 3.86 (s, 2H, NH2, exchangeable with
D2O), 3.97 (s, 1H, NH, exchangeable with D2O), 5.53–5.60
(m, 1H, CH, C-6), 7.18–7.38 (m, 5H, Ar-H), 9.98 (s, 1H,









0.78 (s, 3H, CH3, C-19), 0.92 (s, 3H, CH3, C-18), 0.97–1.06
(m, 1H, CH), 1.18–1.26 (m, 4H, 2CH2), 1.43–1.57 (m, 6H,
3CH2), 1.60–1.80 (m, 4H, 2CH2), 1.95–2.00 (m, 1H, CH),
2.32 (s, 3H, N-CH3), 2.40–2.47 (m, 2H, CH2), 2.55–2.62 (m,
1H, CH), 3.53–3.62 (m, 1H, 3-CH), 4.02 (s, 1H, NH, ex-
changeable with D2O), 5.55–5.60 (m, 1H, CH, C-6),









0.81 (s, 3H, CH3, C-19), 0.97 (s, 3H, CH3, C-18), 0.99–1.04
(m, 1H, CH), 1.20–1.25 (m, 4H, 2CH2), 1.42–1.56 (m, 6H,
3CH2), 1.61–1.79 (m, 4H, 2CH2), 1.96–2.02 (m, 1H, CH),
2.39–2.46 (m, 2H, CH2), 2.53–2.60 (m, 1H, CH), 3.54–3.60
(m, 1H, 3-CH), 4.15 (s, 1H, NH, exchangeable with
D2O), 5.52–5.58 (m, 1H, CH, C-6), 7.19–7.36 (m, 5H,










0.80 (s, 3H, CH3, C-19), 0.94 (s, 3H, CH3, C-18), 0.99–1.06
(m, 1H, CH), 1.21–1.27 (m, 4H, 2CH2), 1.41–1.59 (m, 6H,
3CH2), 1.62–1.81 (m, 4H, 2CH2), 1.98–2.04 (m, 1H, CH),
2.35 (s, 3H, N-CH3), 2.42–2.49 (m, 2H, CH2), 2.54–2.60 (m,
1H, CH), 4.00 (s, 1H, NH, exchangeable with D2O),
5.52–5.61 (m, 1H, CH, C-6), 10.86 (br. s, 1H, OH, exchan-
geable with D2O)




A solution of compounds 1a,b (150 mg) in acetyl chloride or trifluoroacetic anhydri-
de (5 mL) was stirred at room temperature for 24 hours. The reaction mixture was pou-
red into ice-water, the separated solid was filtered off, dried and crystallized from the
proper solvent to yield the compounds 4a,b and 5a,b, respectively (Scheme 2).




A mixture of compounds 1a,b (5 mmol) and catalytic reagents, namely, palladium-
-charcoal or platinum oxide-charcoal (Adam’s catalyst) (50 mg) in absolute ethanol (25
mL) was shaken at 75 °C under hydrogen (5  105 Pa) for 7 hours and filtered. The filtra-
te was evaporated under reduced pressure, the residue was solidified with ether, the se-
parated solid was filtered off, dried and crystallized from the proper solvent to yield the
compounds 6a,b and 7a,b, respectively (Scheme 2).
49











0.83 (s, 3H, CH3, C-19), 0.95 (s, 3H, CH3, C-18), 1.00–1.05
(m, 1H, CH), 1.21–1.27 (m, 4H, 2CH2), 1.39–1.58 (m, 6H,
3CH2), 1.63–1.82 (m, 4H, 2CH2), 1.96–2.05 (m, 1H, CH),
2.40–2.46 (m, 2H, CH2), 2.51–2.59 (m, 1H, CH), 3.98 (s,
1H, NH, exchangeable with D2O), 5.50–5.60 (m, 1H, CH,









0.77 (s, 3H, CH3, C-19), 0.94 (s, 3H, CH3, C-18), 0.99–1.06
(m, 1H, CH), 1.19–1.25 (m, 4H, 2CH2), 1.40–1.56 (m, 6H,
3CH2), 1.61–1.83 (m, 4H, 2CH2), 1.97–2.00 (m, 1H, CH),
2.38 (s, 3H, N-CH3), 2.41–2.48 (m, 2H, CH2), 2.54–2.58 (m,
1H, CH), 3.52–3.60 (m, 1H, 3-CH), 3.64–3.68 (m, 4H,
2CH2), 3.98 (s, 1H, NH, exchangeable with D2O),
5.55–5.65 (m, 1H, CH, C-6), 8.40 (s, 1H, NH, exchangeable








0.79 (s, 3H, CH3, C-19), 0.87 (s, 3H, CH3, C-18), 0.97–1.04
(m, 1H, CH), 1.16–1.25 (m, 4H, 2CH2), 1.40–1.54 (m, 6H,
3CH2), 1.60–1.80 (m, 4H, 2CH2), 1.98–2.03 (m, 1H, CH),
2.42–2.50 (m, 2H, CH2), 2.58–2.64 (m, 1H, CH), 3.55–3.61
(m, 1H, 3-CH), 3.66–3.69 (m, 4H, 2CH2), 4.00 (s, 1H, NH,
exchangeable with D2O), 5.51–5.62 (m, 1H, CH, C-6),
7.19–7.38 (m, 5H, Ar-H), 8.32 (s, 1H, NH, exchangeable
with D2O), 10.00 (s, 1H, OH, exchangeable with D2O)
Synthesis of 3-hydroxy-17-methyl amino-androst-5-ene-17-carboxamide (8a)
and 3-hydroxy-17-phenyl amino-androst-5-ene-17-carboxamide (8b)
A solution of compounds 1a,b (1 mmol) in sulphuric acid (0.5 mol L–1, 10 mL) was
heated at 50 °C for 5 hours, then left overnight at room temperature. The reaction mixtu-
re was poured into ice water, the separated product was filtered off, washed with water,
dried and crystallized from the proper solvent to give the corresponding carboxamide
derivatives 8a,b, respectively (Scheme 3).
Synthesis of 3-hydroxy-17-methyl amino-androst-5-ene-17-carboxylic acid (9a)
and 3-hydroxy-17-phenyl amino-androst-5-ene-17-carboxylic acid (9b)
A mixture of compounds 1a,b (1 mmol) in alcoholic sodium hydroxide (25 mL, 10%)
was refluxed for 7 hours. The reaction mixture was acidified with 1 mol L–1 hydrochloric
acid (pH  3). The separated product was filtered off, washed with water, dried and cry-
stallized from the proper solvent to give the corresponding acid derivatives 9a,b, respec-
tively (Scheme 3).
Synthesis of 3-oxo-17-methyl amino-androst-5-ene-17-carboxylic acid (10a)
and 3-oxo-17-phenyl amino-androst-5-ene-17-carboxylic acid (10b)
A mixture of compounds 1a,b (2 mmol) and Killian reagent (6 mL) prepared from
potassium dichromate (6 g) and concentrated sulfuric acid (8 mL) in water (27 mL) in
glacial acetic acid (15 mL) was stirred at room temperature for 1.5 hours. The reaction
mixture was warmed with methanol (15 mL) to destroy excess chromic acid, then it was
poured into ice-water; the solid formed was filtered off, washed with water, dried and
crystallized from the proper solvent to give 3-oxo-17-substituted amino-androst-5-ene-
17-carboxylic acids 10a,b, respectively (Scheme 3).
Synthesis of 17-(2-imidazolyl)-17-methyl amino-androst-5-ene-3-ol (11a)
and 17-(2-imidazolyl)-17-phenyl amino-androst-5-en-3-ol (11b)
A mixture of compounds 1a,b (1 mmol) in ethylene diamine (15 mL) was refluxed
for 3 hours. The reaction mixture was poured into water, the formed solid was filtered
off and crystallized from the proper solvent to give the corresponding imidazole deriva-
tives 11a,b, respectively (Scheme 3).
Biological screening
Animals. – Biological experiments were made according to the ethical rules and ani-
mals were obtained from the animal house colony of the National Research Center, Cairo,
Egypt. All animals were allowed free access to water and were kept on a constant stan-
dard diet. Prepubertal Sprague-Dawley male albino rats 21 day old (45–50 g), were used
to investigate the effect of the tested compounds on the development of male sex organs.
Adult male albino rats (150 days) weighting (150–200 g) were used in the present work
to evaluate the androgenic-anabolic activity of all newly synthesized derivatives.
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Acute toxicity (LD50)
Male rats were used to determine intraperitoneal LD50 of the tested compounds.
Prior to determination of the LD50 value, a range finding screen was conducted using 20
rats each treat with a tested compound at a dose ranging from 3–2000 mg kg–1. Based on
the mortality observed within 14 days, the doses used for the LD50 determination were
3, 10, 30, 100, 300, 1000, 2000 mg kg–1 for compounds administered by intraperitoneal in-
jection as a 10% solution in dimethyl sulphoxide (DMSO). Control animals received in-
traperitoneal injections of DMSO. For each concentration and control, ten male rats were
injected with the tested compounds twice daily for two weeks to kill any swirved ani-
mals. From the mortality data of all tested animals, the intraperitoneal LD50 values for
each agent were determined according to Austen et al. (22) (Table III).
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Table III. Evaluation of LD50 of the synthesized compounds
Compound LD50 (mg kg–1)a
Testosterone 2751  5
Dehydroepiandrosterone 3411  4
1a 3211  8
1b 2561  5
2a 2818  5
2b 2913  6
3a 2781  4
3b 2750  6
4a 2713  6
4b 2514  6
5a 3164  8
5b 3000  7
6a 2634  8
6b 2894  7
7a 2856  7
7b 2646  7
8a 2895  7
8b 2648  7
9a 2865  6
9b 2743  5
10a 2891  5
10b 2914  4
11a 2988  5
11b 2755  3
a Mean  SD, n = 24.
Androgenic-anabolic activity
Groups of immature male albino rats (each group contains 8 animals), 21 days old,
received subcutaneously particular target compounds and testosterone as reference
standard at a total dose of 0.7 mg kg–1 according to the following design: group 1 recei-
ved the vehicle (DMSO); group 2 received the testosterone reference standard in vehicle
(DMSO) (at a dose of 0.1 mg kg–1 daily for 7 days); group 3 was subdivided into 22 sub-
groups, each received individually one of the tested compounds (at a dose of 0.1 mg
kg–1 daily for 7 days).
Androgenic-anabolic activity of all newly synthesized compounds was measured
according to the reported procedure (23, 24) (Tables IV and V).
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Table IV. Androgenic-anabolic activity of newly synthesized compounds
Compound Mass of prostate gland (g)a Mass of levator ani-muscle (g)a Ratiob
Control 0.20  0.02 0.18  0.02 –
Testosterone 0.76  0.01 0.20  0.01 0.05
1a 0.32  0.01 0.44  0.15 2.20
1b 0.39  0.01 0.54  0.01 1.90
2a 0.41  0.01 0.56  0.01 1.82
2b 0.39  0.01 0.42  0.13 1.28
3a 0.71  0.01 0.73  0.02 0.97
3b 0.66  0.02 0.68  0.02 1.09
4a 0.73  0.01 0.75  0.02 1.08
4b 0.44  0.02 0.58  0.01 1.68
5a 0.31  0.01 0.43  0.16 2.30
5b 0.75  0.01 0.76  0.02 1.06
6a 0.81  0.02 0.19  0.01 0.02
6b 0.83  0.026 0.21  0.02 0.06
7a 0.81  0.01 0.23  0.01 0.09
7b 0.82  0.02 0.22  0.02 0.06
8a 0.82  0.01 0. 21  0.02 0.06
8b 0.87  0.01 0.25  0.01 0.10
9a 0.83  0.02 0.27  0.01 0.14
9b 0.86  0.02 0.28  0.01 0.16
10a 0.91  0.03 0.30  0.03 0.17
10b 0.96  0.02 0.31  0.02 0.17
11a 0.97  0.02 0.30  0.02 0.16
11b 0.96  0.02 0.24  0.02 0.08
a Mean  SEM (n = 8).
b Ratio of the mass gained by the levator ani-muscle to the mass gained by the prostate gland.
Groups of prepubertal albino rats (n = 8) 21 days old, were kept on a constant diet
and tap water. Each animal was given daily a subcutaneous injection of the tested com-
pound as well as testosterone as reference standard at a dose of 0.1 mg kg–1 for seven
days. On day eight (22–26 hours after the last injection), the animals were killed, dissec-
tion of the levator ani muscle, the ventral prostate gland, testis, seminal vesicles, vas de-
ference and epididymis were carried out and were weighed.
The ratio of the mass gain of the levator ani-muscle to the mass gain of the ventral
prostate gland was calculated where the mass gain of the levator ani muscle indicates
53
N. A. Abd El-Latif et al.: New steroidal derivatives synthesized using 3-hydroxyandrosten-17-one as starting material, Acta Pharm.
58 (2008) 43–59.
Table V. Effect of synthesized compounds on androgenic organs
Compound
Mass (g)a
Epididymis Testis Seminal vesicles Vasdifference
Testosterone 0.36  0.03b 0.70  0.02b 0.63  0.01b 0.19  0.012b
1a 0.31  0.04c 0.45  0.04c 0.59  0.01bc 0.72  0.08c
1b 0.36  0.03b 0.68  0.02 0.58  0.01b 0.19  0.01b
2a 0.30  0.03c 0.43  0.04 0.56  0.02bc 0.73  0.021b
2b 0.28b  0.02c 0.41  0.02 0.41  0.02bc 0.13  0.02bc
3a 0.29b  0.02c 0.39  0.02 0.39  0.02bc 0.14  0.02bc
3b 0.37a  0.03b 0.74  0.03 0.68  0.02b 0.13  0.02bc
4a 0.37a  0.03b 0.74  0.03 0.61  0.03b 0.12  0.02bc
4b 0.15b  0.02c 0.34  0.03 0.38  0.01c 0.29  0.04c
5a 0.37a  0.03b 0.74  0.03 0.61  0.02b 0.30  0.05c
5b 0.22b  0.02c 0.31  0.04 0.41  0.03b 0.22  0.06b
6a 0.34a  0.03b 0.39  0.04 0.54  0.03b 0.42  0.02b
6b 0.35a  0.02b 0.42  0.03 0.45  0.02b 0.22  0.02b
7a 0.36a  0.02b 0.51  0.05 0.48  0.02b 0.32  0.02b
7b 0.32a  0.04b 0.52  0.04 0.56  0.02b 0.23  0.02b
8a 0.32  0.05b,c 0.42  0.03 0.43  0.03b 0.17  0.02b
8b 0.32  0.03b,c 0.39  0.02 0.42  0.02b 0.25  0.03b
9a 0.32  0.02b,c 0.56  0.02 0.52  0.02b 0.21  0.02b
9b 0.32  0.01b,c 0.47  0.01 0.41  0.02b 0.22  0.02b
10a 0.22  0.01b,c 0.46  0.01 0.41  0.02b 0.22  0.02b
10b 0.22  0.02b,c 0.42  0.02 0.52  0.02b 0.21  0.02b
11a 0.24  0.02b,c 0.43  0.01 0.54  0.02b 0.22  0.02b
11b 0.52  0.02b,c 0.48  0.013 0.56  0.02b 0.22  0.02b
a Mean  SE (n = 8).
b Significantly different from normal control value (p  0.05).
c Significantly different from testosterone value (p  0.05).
the anabolic effect and the mass gain of the ventral prostate gland shows the androgenic
effect of the tested compounds.
RESULTS AND DISCUSSION
In the present work, we utilized Strechker synthesis to introduce the 17-cyano-
-17-substituted amino group into synthesized compounds, because the cyano group
provides a wide variety of biological activities. Amino group serves to form water-solu-
ble salts that increase the pharmacokinetics and pharmacodynamics of steroids such as
Stanazolole® due to its increased absorption and distribution in plasma protein.
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Compounds 1a,b were obtained by reacting dehydroepiandrosterone with primary
amines, namely, methylamine or aniline in the presence of potassium cyanide. Reaction
of compounds 1a,b with dimethylamino-2-chloroethane in the presence of triethylamine
as catalyst yielded N,N-dimethylethane derivatives 2a,b while the reaction of 1a,b with
piperidine in the presence of paraformaldehyde gave the piperidyl derivatives 3a,b. The
IR spectra of 1-3 showed the absence of bands corresponding to n(C=O) for dehydro-
epiandrosterone and the presence of a band at 2224–2227 cm–1 corresponding to n(CN),
and a broad band at 3448–3396 cm–1 corresponding to n(NH) for dehydroepiandrostero-
ne. The syntheses of compounds 1-3 are outlined in Scheme 1.
Acylation of the resulting compounds 1a,b with acetylchloride or trifluoroacetic an-
hydride in boiling toluene gave the corresponding diprotected derivatives 4a,b and
5a,b, respectively. Also, catalytic hydrogenation of 1a,b with palladium charcoal (Pd/
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charcoal) afforded the corresponding primary amines 6a,b without affecting the 	5-ene
double bond, whereas with Adam’s catalyst (PtO2) it afforded the corresponding primary
amines 7a,b with hydrogenated 	5-ene double bond. The IR spectra of 4 and 5 showed
the absence of bands n(OH) at 3448–3378 cm–1 for the starting compound and the pres-
ence of bands corresponding to n(C=O) for 4 and 5. Also, the IR spectra of 6 and 7 sho-
wed the absence of bands n(CN) at 2224 cm–1 for the starting compound and the presen-
ce of bands corresponding to n(NH2) for 6 and 7. The syntheses of compounds 4-7 are
outlined in Scheme 2.
Hydrolysis of compounds 1a,b with sulphuric acid (H2SO4, 0.5 mol L–1) or alcoholic
sodium hydroxide (10%) gave the corresponding amide derivatives 8a,b and the carbo-
xylic acids 9a,b, respectively. On the other hand, oxidation of 1a,b with Killian reagent
(chromic acid, as oxidizing agent) afforded the corresponding 3-oxo-analogues 10a,b
with hydrolyzed cyano group to carboxylic group. Condensation of compounds 1a,b wi-
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(K Cr O /H SO )2 2 7 2 4
Killian's catalyst
Scheme 3
th 1,2-diaminoethane gave the corresponding imidazole derivatives 11a,b. The IR spec-
tra of 8-11 showed the absence of bands corresponding to n(CN) for 1 and the presence
of bands corresponding to n(C=O) for compounds 8-10 and n(NH) for 11. The syntheses
of compounds 8-11 are outlined in Scheme 3.
Acute toxicity
Initially, acute toxicity of the synthesized compounds was assayed by determining
their LD50. Interestingly, most compounds were less toxic than the reference drug, ex-
cept compounds 1b, 4b, 6a, 7b and 8b (Table III). The LD50 (rats) was determined by in-
jecting different increasing doses and calculating the dose that killed 50% of the animals.
Androgenic-anabolic activity
The newly synthesized compounds were then pharmacologically screened for their
androgenic-anabolic potency on male albino rats.
From Tables IV and V, the ratio of the mass gained by the levator ani-muscle to the
mass gained by the prostate gland was calculated, where the former indicates the anabo-
lic activity and the latter shows the androgenic effect of the tested compounds. It was re-
vealed that all the tested compounds have significant androgenic as well as anabolic ef-
fects. Regarding the androgenic activity indicated by the mass gained by the prostate
gland, compounds 3a, 6b-11b showed high androgenic activity.
Compounds 1a, 1b, 2a, 2b, 3b, 4a, 4b, 5a and 5b showed potent anabolic activities
where the ratio of mass gained by the levator ani-muscle (anabolic) to the mass gained
by the ventral prostate were 2.20, 1.90, 1.82, 1.28, 1.09, 1.08, 1.68, 2.30 and 1.06 (Table IV).
It is evident from Table V that compounds 3a, 6b-11b significantly increase the mass
of male sex organs. Compound 5a showed high anabolic activity, increasing the mass of
both levator-ani muscle and prostate gland in a statistically significant manner. It increa-
sed the mass of the testicles but in a non-significant manner.
Structure activity relationship (SAR)
The presence of some groups (hydrogen bond donors) is beneficial for androgenic
activities. The activity was found to decrease in the following order: 6a, 6b, 8a, 7b, 11b
and 7a. It was found that the anabolic activity was decreasing in the order: 5a, 1a, 1b, 4b,
2a, 3b, 4a and 5b, indicating that the presence of hydrogen bond acceptor is an impor-
tant beneficial factor for anabolic activity.
CONCLUSIONS
Twenty-two steroidal derivatives were synthesized and tested for their androgenic-
-anabolic activities. The substituted steroidal structure containing 5-ene double bonds
was found essential for androgenic-anabolic activity. A future work will involve the de-
sign of steroidal molecules of such features.
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S A @ E T A K
Novi steroidni derivati sintetizirani iz 3-hidroksiandrosten-17-ona
NEHAD A. ABD EL-LATIF, MOHAMED M. ABDULLA i ABD EL-GALIL E. AMR
U radu je opisana sinteza novih steroidnih derivata 1-11 koriste}i 3-hidroksiandro-
sten-17-on (dehidroepiandrosteron) kao po~etnu supstanciju. Androgeno-anaboli~ko
djelovanje tih spojeva uspore|ivano je s djelovanjem testosterona kao pozitivnom kon-
trolom. Navode se detaljni sintetski postupci, spektroskopska karakterizacija i podaci o
toksi~nosti (LD50).
Klju~ne rije~i: dehidroepiandrosteron, steroidni derivati, androgeno-anaboli~ki steroidi
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